Investigational drug · Phase 2
AT101
Also called: Anti-CD19 Chimeric Antigen Receptor T cell
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for B-cell Non Hodgkin Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: May 26, 2022 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
28
Any phase or sponsor naming "AT101"
First trial start
2022
Mar 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AT101", any sponsor or status.
Conditions studied
As listed on its trial records.
- B-cell Non Hodgkin Lymphoma
Approved drugs for the same conditions: Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "AT101" as an intervention, largest first.
- A Randomized Trial of Vaccine Adherence in Young Injection Drug UsersPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00244374 · 546 participants · Start Aug 2004 · Primary completion Jun 2008
Drug: Hepatitis A & B vaccine · For: Medication Adherence; Substance Abuse, Intravenous; Risk Behavior and 3 more
Sites: San Francisco, California
- A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)Pivotal-lookingCompleted
Ascenta TherapeuticsIndustry
NCT00571675 · 220 participants · Start Oct 2007 · Primary completion Sep 2010
Drug: AT-101, prednisone and docetaxel; placebo, prednisone and docetaxel · For: Hormone Refractory Prostate Cancer
Sites: Colorado Springs, Colorado; New Port Richey, Florida; Ocoee, Florida · 35 sites in all
- Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High ExpressionPivotal-lookingStatus unknown
Third Military Medical UniversityAcademic, hospital or other
NCT01977209 · 204 participants (planned) · Start Sep 2013 · Primary completion Feb 2016
Drug: Gossypol; Placebo · For: Non-small Cell Lung Cancer
Sites: Chongqing, China · 6 sites in all
Ascenta TherapeuticsIndustry
NCT00544960 · 106 participants · Start Sep 2007 · Primary completion Nov 2008
Drug: AT-101 and docetaxel; placebo and docetaxel · For: Non-small Cell Lung Cancer
Sites: Durham, North Carolina; Arkhangelsk, Russia; Chelyabinsk, Russia · 18 sites in all
AbClonIndustry
NCT05338931 · 82 participants (planned) · Start Mar 15, 2022 · Primary completion Mar 15, 2030
Drug: AT101(Anti-CD19 Chimeric Antigen Receptor T cell) · For: B-cell Non Hodgkin Lymphoma
Sites: Seoul, South Korea
- Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPCCompleted
Ascenta TherapeuticsIndustry
NCT00286793 · 76 participants · Start Feb 2006 · Primary completion Nov 2009
Drug: AT-101 · For: Prostate Cancer
Sites: Hot Springs, Arkansas; Fort Meyers, Florida; Chicago, Illinois · 13 sites in all
National Cancer Institute (NCI)NIH
NCT00540722 · 56 participants · Start Jan 2008 · Primary completion Jun 2012
Drug: R-(-)-gossypol acetic acid · For: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma and 1 more
Sites: Birmingham, Alabama; Tampa, Florida; Baltimore, Maryland · 8 sites in all
National Cancer Institute (NCI)NIH
NCT00666666 · 55 participants · Start Jul 2009 · Primary completion May 2011
Drug: AT-101; Bicalutamide · For: Adenocarcinoma of the Prostate; Stage IV Prostate Cancer
Sites: Chicago, Illinois; Ann Arbor, Michigan; New Brunswick, New Jersey · 4 sites in all
University of Michigan Rogel Cancer CenterAcademic, hospital or other
NCT01633541 · 55 participants · Start Mar 2012 · Primary completion Nov 6, 2021
Drug: AT-101; Docetaxel and 2 more · For: Laryngeal Cancer
Sites: Ann Arbor, Michigan
Zhejiang Cancer HospitalAcademic, hospital or other
NCT06133088 · 53 participants (planned) · Start Aug 1, 2023 · Primary completion Dec 31, 2024
Drug: dalpiciclib; fluvestrant; compound gossypol acetate tablets · For: Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma.
Busato D, Argenziano M, Polano M, et al. · Biomed Pharmacother 2026
- Impact of Prophylactic Steroids on Chimeric Antigen Receptor T-Cell Related Toxicity for Relapsed and Refractory Non-Hodgkin Lymphoma.
Habib A, Youssef Y, Welkie RL, et al. · Transplant Cell Ther 2026
- Teclistamab in relapsed, multirefractory acquired hemophilia A after failure of anti-CD19 chimeric antigen receptor T-cell therapy.
Dobbelstein CE, Stoyanov K, Aleksandrova K, et al. · J Thromb Haemost 2026
- A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.
Seng MS, Guo Z, Ng KS, et al. · Blood Cancer Discov 2026
- Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients.
Tannumsaeng S, Anurathapan U, Sermcheep A, et al. · Cancer Chemother Pharmacol 2026
- Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis.
Gupta S, Seshadri MR, Dandekar R, et al. · medRxiv 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.